Clinigen Group Plc announced earnings results for the six months ended December 31, 2017. For the period, the company reported group revenues increased around 28%. This is higher than the growth in gross profit due primarily to an increased level of pass through costs within the early access part of Unlicensed Medicines. Following the acquisitions and the payment of the final scheduled deferred consideration on the Link acquisition, net debt increased to around £142 million as at December 31, 2017.